Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04110054 · ClinicalTrials.gov registry record · Phase 2
Evaluation of S-600918 in Adults With Refractory Chronic Cough
A Phase 2 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 406
- Enrollment target
NCT04110054: Completed Phase 2 study, sponsored by Shionogi.
NCT04110054 is a Phase 2 study that has completed, run by Shionogi. The registered enrollment target is 406 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (205% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04110054, a Phase 2 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 406 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.
Primary Outcome
Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour in 24 hours at each visit with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the log-transformed coughs per hour in 24 hours at bas
Interventions
- DRUG S-600918
- DRUG Placebo to S-600918
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
What the finished NCT04110054 record still lists
NCT04110054 is an interventional study that assigns participants to a tested intervention. The registered 406 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (205% higher).
The record links to 0 conditions, and to 2 interventions - of which S-600918 is the first listed.
NCT04110054 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04110054 about?
NCT04110054 is a clinical study titled "Evaluation of S-600918 in Adults With Refractory Chronic Cough". The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.
What is the current status of trial NCT04110054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 406 participants. The study started on 2020-02-13. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT04110054?
The interventions under investigation include: S-600918 (DRUG), Placebo to S-600918 (DRUG).
Who is sponsoring clinical trial NCT04110054?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04110054's enrollment target sits among peer trials
406 94th of 2000 higher than 1,906 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
- NCT06585787 · 406 participants · Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI